The clinical application of ICIs targeting CTLA-4 or PD-1/PD-L1 to reactivate the immune response against cancer have achieved favourable outcomes in advanced CRC, especially for patients with MSI-H/dMMR (20, 49). The gene discussed is CD274; the disease is colorectal carcinoma.